Stay updated with breaking news from Pathol Transl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ENHERTU demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of...
Daiichi Sankyo and AstraZeneca’s ENHERTU also demonstrated a clinically meaningful progression-free survival improvement in patients with HER2 ultralow expression Plans for global regulatory...
Daiichi Sankyo and AstraZeneca's ENHERTU also improved progression-free survival by 22 months versus T-DM1 in patients previously treated with HER2 directed therapy in the DESTINY-Breast03 phase
Approval broadens indication for Daiichi Sankyo and AstraZeneca's ENHERTU across Europe to earlier use in HER2 positive metastatic breast cancer Based on groundbreaking DESTINY-Breast03 results
Investegate announcements from AstraZeneca PLC, Enhertu approved in EU for HER2-positive mBC